Other studies attempted CSF testing of phosphorylated-tau/Aβ ratio for the diagnosis of Alzheimer's disease in current clinical practice, although very limited clinical uncertainties were addressed [163]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.